胺碘酮预防食管切除术后心房颤动
该回顾性队列研究经倾向性评分匹配110对患者,发现预防性静脉胺碘酮(43.75 mg/h持续96小时,总剂量4200 mg)可降低食管切除术后需治疗的心房颤动发生率(15.5% vs 29.1%),但不缩短住院时间,且低血压、心动过缓及QTc延长发生率显著增高。
要点
- 预防性静脉胺碘酮降低食管切除术后需治疗的心房颤动发生率。
- 胺碘酮不缩短术后住院时间,也不改变肺部并发症或死亡率。
- 胺碘酮组低血压、心动过缓及QTc延长发生率显著更高。
核心结论
- 预防性静脉胺碘酮与食管切除术后心房颤动发生率降低相关,但不缩短术后住院时间。
- 预防性静脉胺碘酮与低血压、心动过缓及校正QT间期延长相关。
研究设计与样本
- 回顾性队列研究,初始队列309例食管切除术患者。
- 经倾向性评分匹配后,胺碘酮组110例与对照组110例进行比较。
- 胺碘酮给药方式为43.75 mg/h持续静脉输注96小时,总剂量4200 mg。
主要发现
- 两组术后中位住院时间、肺部并发症发生率及死亡率无显著差异。
临床怎么用
- 食管切除术后可考虑预防性静脉胺碘酮以降低需治疗的心房颤动,但需监测低血压、心动过缓和QTc延长。
- 不应期望胺碘酮预防能缩短术后住院时间。
局限性
- 回顾性队列设计,即使经倾向性评分匹配仍可能存在残余混杂。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Atrial fibrillation (AF) is a common complication after esophagectomy and is associated with symptoms, hemodynamic instability, prolonged hospital stay, and an increased incidence of mortality. Our objective was to determine the efficacy and safety of intravenous amiodarone for prophylaxis of postesophagectomy AF. METHODS: In this retrospective cohort study, 309 patients who underwent esophagectomy formed the initial cohort. Following propensity score-matching, 110 patients who received prophylactic amiodarone 43.75 mg/hour via continuous intravenous infusion over 96 hours (total dose, 4200 mg) were matched to a control group of patients who did not undergo amiodarone prophylaxis (n = 110). The propensity score was obtained using a multivariate logistic regression model with amiodarone as the variable and the following covariates: age, sex, surgical approach, history of neoadjuvant chemotherapy and/or radiation, chronic obstructive pulmonary disease, heart failure, cardiovascular disease, alcohol use (>7 drinks/week), preadmission β-blockers discontinued during hospitalization, preoperative use of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, preoperative use of corticosteroids, postoperative use of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, postoperative use of corticosteroids, postoperative use of statins, and preoperative Charlson comorbidity index. RESULTS: The incidence of AF requiring treatment due to rapid ventricular rate and symptoms was lower in the amiodarone group (17 out of 110 [15.5%] vs 32 out of 110 [29.1%]; odds ratio, 0.45; 95% confidence interval, 0.23-0.86; P = .015). There were no significant differences between the groups in median postoperative length of hospital stay, incidence of pulmonary complications, or mortality. The incidences of hypotension requiring treatment (42.7% vs 21.8%; P = .001), bradycardia (8.2% vs 0.0%; P = .002), and corrected QT interval prolongation (10.9% vs 0.0%; P ≤ .0001) were significantly higher in the amiodarone group. CONCLUSIONS: Prophylactic intravenous amiodarone is associated with a reduction in the incidence of AF following esophagectomy, but is not associated with shorter postoperative length of hospital stay. Intravenous amiodarone for prophylaxis of postesophagectomy AF is associated with hypotension, bradycardia, and corrected QT interval prolongation.
引用
- Tisdale JE, Jaynes HA, Watson MR, et al. Amiodarone for prevention of atrial fibrillation following esophagectomy. J Thorac Cardiovasc Surg. 2019. PMID: 30853230. doi:10.1016/j.jtcvs.2019.01.095
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。